810nm & 1070nm - What is the difference?

This transcranial photobiomodulation (PBM) system was recently modified to use 1070nm LEDs through a collaboration between Quietmind Foundation and is based on our 15 years of applied clinical research and practice. This new model PBM device represents a significant technical advance in the transcranial PBM field offering deeper penetration and clinical changes in cellular activity and gene expression that directly prevent cell death and promote regeneration.

The new unit covers the entire skull including the brain stem and cerebellum and offers intensity and single hertz pulse control (1-20,000hz) for more powerful clinical protocol control and improved outcomes. Quietmind Foundation, along with our colleagues at Baylor Research Institute (BRI), an affiliate of Baylor Scott & White Health and Texas A&M School of Medicine, conducted one of the first human clinical trials using neuropsychological and advanced neuroimaging assessments to evaluate this innovative approach to transcranial PBM. The device used in the trial was the 1070nm wavelength, produced rapid (<30 days), significant improvement in both mood and memory loss symptoms. This unit represents the next generation of PBM technology, based on the QMF-BRI research unit that can safely and reliably offer home-based, self-administered, affordable PBM treatment. This technology offers real hope to people dealing with a wide range of neurodegenerative, chronic pain, and neuropsychiatric disorders.  

The 810nm model, while not as powerful as the 1070nm version has been shown to help improve cognitive and behavioral symptoms associated with stroke, mild head injury and post-concussion chronic pain conditions. Recently there is evidence that 810nm can be useful in improving cognitive challenges associated with dementia. We advocate the broader application of photo-stimulation, including QEEG-targeted pulsation, which uniquely differentiates this PBM device since the more mitochondria that are stimulated the greater the increase in ATP produced and improved regional cerebral blood flow is generated.
English
English